Clinical Report: FDA approves HIV treatment for newborns
Overview
The FDA has approved dolutegravir (Tivicay PD) for treating HIV in newborns from birth to 4 weeks of age who weigh at least 2 kg. This approval is based on data from the IMPAACT 2023 study, which demonstrated comparable dolutegravir levels in newborns to those associated with efficacy in adults.
Background
HIV infection poses a significant risk to the immune system, leading to serious infections or cancer and potentially progressing to AIDS without treatment.
Data Highlights
Study
Participants
Follow-up Duration
Key Findings
IMPAACT 2023
48 newborns exposed to HIV-1
16 weeks
Dolutegravir levels comparable to adults; safety profile similar to older patients.
Key Findings
The FDA approved dolutegravir for newborns from birth to 4 weeks weighing at least 2 kg.
Dolutegravir was previously approved for adults and pediatric patients older than 4 weeks.
Participants in the IMPAACT 2023 study received dolutegravir in combination with standard-of-care antiretroviral medications.
Dolutegravir levels in newborns were comparable to those associated with efficacy in adults.
The safety profile in newborns was similar to that observed in older pediatric and adult patients.
Clinical Implications
Healthcare providers should consider dolutegravir as a treatment option for newborns at risk of HIV infection.
Conclusion
The approval of dolutegravir for newborns represents a significant advancement in the treatment of HIV in this population, providing a new tool to combat mother-to-child transmission.
